Osteosarcoma in Dogs: Bone Cancer Symptoms and Treatment

Osteosarcoma (OSA) is the most common primary bone tumour in dogs, accounting for approximately 85 per cent of all skeletal cancers in the species. It is an aggressive malignancy arising from the cells that produce bone (osteoblasts), and it is notorious for its rapid local growth and high metastatic potential. Approximately 10,000 dogs are diagnosed with osteosarcoma each year in the United States alone, making it a significant concern in canine oncology.

"Osteosarcoma is one of the most heartbreaking diagnoses in veterinary medicine because it disproportionately affects large, active dogs in what should be the prime of their lives. But with modern treatment protocols, many dogs can enjoy months to years of quality time with their families." — Dr. Sarah Chen, DVM

The tumour most commonly develops in the appendicular skeleton — the long bones of the legs. The most frequently affected sites are the distal radius (near the wrist), the proximal humerus (upper shoulder area), the distal femur (above the knee), and the proximal tibia (below the knee). A useful mnemonic veterinary students learn is 'away from the elbow, towards the knee' — reflecting the predilection for the metaphyseal regions of these bones, where the most active bone growth occurs. Osteosarcoma can also arise in the axial skeleton (skull, spine, ribs, pelvis), though this is less common and carries a somewhat different prognosis.

What makes osteosarcoma particularly devastating is its metastatic behaviour. At the time of diagnosis, approximately 90 per cent of dogs already have microscopic metastatic disease — meaning cancer cells have spread to distant sites (most commonly the lungs) even though they may not yet be visible on X-rays or scans. This is why treating the primary tumour alone is insufficient for most patients.

Osteosarcoma shows a striking predilection for large and giant breed dogs. The risk increases proportionally with body size — dogs weighing over 40 kg are at the highest risk. The breeds most commonly affected include Great Danes, Irish Wolfhounds, Rottweilers, Greyhounds, Scottish Deerhounds, Saint Bernards, Leonbergers, Doberman Pinschers, and German Shepherds. Some studies have reported that Great Danes have up to a 200-fold increased risk compared to small breeds.

The typical age at diagnosis is between seven and ten years, though osteosarcoma can occur in younger dogs — particularly in giant breeds, where it sometimes appears as early as two to three years of age. Male dogs appear to be slightly more commonly affected than females in most studies, though the gender difference is modest. Interestingly, neutered dogs of both sexes may have a slightly higher risk than intact dogs, possibly due to the role of sex hormones in bone development and closure of growth plates.

The link between rapid skeletal growth and osteosarcoma risk is thought to be the underlying mechanism for the breed predisposition. Areas of the skeleton with the most active growth during development — the metaphyseal regions of the long bones — are precisely where osteosarcoma most commonly arises. Some researchers have also identified genetic loci associated with increased risk in certain breeds, supporting the role of hereditary susceptibility.

Smaller breeds are not immune to osteosarcoma, but when bone tumours occur in small dogs, they are more likely to be located in the axial skeleton and may behave somewhat less aggressively. Regardless of breed, any dog presenting with unexplained lameness and bone swelling — particularly in the metaphyseal region of a long bone — should be evaluated promptly for possible bone cancer.

The most common presenting sign of osteosarcoma is lameness — often progressive and initially intermittent. Owners typically describe a gradual onset limp that may improve temporarily with rest or anti-inflammatory medications but always returns and worsens. The lameness is caused by the tumour destroying normal bone and stretching the periosteum (the pain-sensitive membrane surrounding the bone), which produces significant discomfort.

Swelling at the tumour site is another key sign, though it may not be obvious in the early stages, especially in muscular or heavy-coated breeds. As the tumour grows, a firm, non-mobile swelling becomes palpable over the affected bone. Dogs often show signs of pain that go beyond simple limping — they may be reluctant to play, have difficulty rising, guard the affected limb, or become irritable when the area is touched.

In some cases, the first sign of osteosarcoma is a pathological fracture — the weakened bone breaks during normal activity or minor trauma. This is a distressing presentation, as the dog suddenly becomes non-weight-bearing on the limb. Pathological fractures are more common when the tumour has extensively eroded the bone cortex, and they carry additional treatment challenges.

Systemic signs such as weight loss, decreased appetite, and lethargy may develop as the disease progresses, particularly if metastatic disease is established. Respiratory signs — coughing, laboured breathing — can indicate lung metastasis, though dogs often do not show respiratory symptoms until metastatic nodules are quite advanced. The insidious nature of early osteosarcoma symptoms means that any persistent lameness in a large or giant breed dog — especially one that does not respond fully to rest and anti-inflammatories within two weeks — warrants X-rays to rule out bone pathology.

Radiographs (X-rays) are usually the first diagnostic step for suspected osteosarcoma and often reveal characteristic changes. The classic radiographic appearance includes a combination of bone destruction (lysis) and new bone formation (proliferation), creating what is known as the 'sunburst' or 'starburst' pattern — radiating spicules of new bone extending outward from the cortex. Other typical findings include cortical destruction, periosteal reaction (lifting and thickening of the periosteum), and soft tissue swelling around the affected bone. An experienced radiologist can often make a presumptive diagnosis from X-rays alone, though confirmation requires tissue sampling.

A bone biopsy — either a core biopsy using a Jamshidi needle or a surgical incisional biopsy — provides definitive histopathological diagnosis. The biopsy confirms osteosarcoma and identifies the specific subtype (osteoblastic, chondroblastic, fibroblastic, or telangiectatic), which can influence prognosis. Fine needle aspirates of bone lesions are less reliable for osteosarcoma due to the hard, mineralised nature of the tumour.

Staging is crucial given the high metastatic rate. Standard staging includes three-view thoracic radiographs to check for visible lung metastases (keeping in mind that micrometastases below 5-6 mm will not be visible), complete blood count and biochemistry panel, urinalysis, and aspiration of regional lymph nodes if they are enlarged. CT scans of the chest are more sensitive than X-rays for detecting small pulmonary metastases and are increasingly recommended as part of standard staging. CT or MRI of the primary tumour helps define its extent and is essential for surgical planning, particularly if limb-sparing surgery is being considered.

Alkaline phosphatase (ALP) levels in the blood have prognostic significance — dogs with elevated ALP at diagnosis tend to have shorter survival times. This simple blood marker helps veterinary oncologists counsel owners about expected outcomes and guides treatment intensity decisions.

The gold standard treatment for appendicular osteosarcoma is amputation of the affected limb followed by chemotherapy. Amputation addresses the primary tumour completely — eliminating the source of severe pain and the risk of pathological fracture. While the idea of amputation is understandably distressing for owners, the vast majority of dogs adapt remarkably well to life on three legs, often returning to near-normal activity within two to three weeks. Owners consistently report that their dog's quality of life improves dramatically after surgery, as the constant bone pain is immediately eliminated.

Chemotherapy following amputation is aimed at the microscopic metastatic disease present in most patients at diagnosis. The most commonly used protocol is carboplatin every three weeks for four to six cycles. Doxorubicin is an alternative, and some protocols alternate between the two. Chemotherapy in dogs is generally well-tolerated — fewer than 5 per cent of dogs experience serious side effects. The combination of amputation plus chemotherapy extends median survival from 4-5 months (amputation alone) to 10-12 months, with approximately 20 per cent of dogs surviving beyond two years.

Limb-sparing surgery is an option for selected patients — typically those with tumours of the distal radius where the anatomy allows replacement of the affected bone segment with a metal implant, a bone graft from a donor, or a sterilised tumour-bone reimplant. Limb-sparing preserves the leg's function but carries higher complication rates, including infection and implant failure. Pet insurance can be invaluable for managing the significant costs associated with these advanced surgical procedures and ongoing chemotherapy.

For dogs that are not candidates for surgery — due to concurrent orthopaedic disease, other health conditions, or owner preference — palliative options include radiation therapy (which can provide meaningful pain relief for several months), bisphosphonates (pamidronate or zoledronate to reduce bone pain), and multimodal pain management with non-steroidal anti-inflammatories, gabapentin, and other analgesics. Palliative care can provide a good quality of life for weeks to months.

Prognosis for osteosarcoma depends heavily on the treatment pursued and several prognostic factors. With amputation alone, median survival is approximately four to five months, with most dogs ultimately succumbing to metastatic disease in the lungs. Adding chemotherapy extends this to a median of 10 to 12 months, and approximately 20 per cent of dogs achieve survival times beyond two years. A small subset of dogs — roughly 10 per cent — appear to be long-term survivors, living three years or more with no evidence of disease recurrence.

Several factors influence individual prognosis. Dogs with tumours in the proximal humerus tend to have shorter survival times than those with distal radius tumours. Normal alkaline phosphatase levels at diagnosis are associated with better outcomes. The presence of visible lung metastases at staging significantly worsens prognosis — these dogs typically survive only one to three months regardless of treatment. Younger dogs (under five years) may have a slightly worse prognosis, though the data is mixed.

Quality of life after amputation and chemotherapy is generally excellent. Studies using owner-reported quality of life questionnaires consistently show that dogs return to most of their normal activities — walking, playing, and even swimming — within weeks of surgery. Owners frequently express surprise at how quickly their dog adapts. The three-legged life is a good life for most dogs. Ensuring adequate exercise suited to your dog's needs and maintaining a healthy weight helps three-legged dogs stay mobile and comfortable.

Ongoing monitoring after treatment typically includes chest X-rays every two to three months for the first year, then every three to four months thereafter. New immunotherapy approaches, including a Listeria-based vaccine (Oncept OSA) and various clinical trials, continue to expand treatment options and may improve outcomes in the future. If your dog is diagnosed with osteosarcoma, asking about clinical trial eligibility can provide access to cutting-edge treatments.